A. Frille (Leipzig, Germany), S. Lang (Jena, Germany)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients
J. Groves (Letchworth(Hertfordshire), United Kingdom), R. Yeo ( Hertfordshire), United Kingdom), Y. Tsang ( Hertfordshire), United Kingdom), N. Shah ( Hertfordshire), United Kingdom), T. Win (Stevenage (Hertfordshire), United Kingdom)
|   |
Upper limbs musculoskeletal disorders after one-year lung cancer resection
A. Heredia Ciuró (Granada, Spain), P. Blasco-Valls (Granada, Spain), J. Rodriguez-Torres (Granada, Spain), F. Quero-Valenzuela (Granada, Spain), A. Ortiz-Rubio (Granada, Spain), M. Valenza (Granada, Spain)
| |
Salvage surgery in patients with locally advanced non-small cell lung cancer – outcomes and longtime results
K. Furrer (Zürich, Switzerland), R. Werner* (Zürich, Switzerland), S. Hillinger (Zürich, Switzerland), D. Schneiter (Zürich, Switzerland), I. Inci (Zürich, Switzerland), I. Opitz (Zürich, Switzerland)
| |
Safety and efficacy of thermal ablation for malignant lung lesions; retrospective case series analysis of the South Wales lung ablation service.
G. Warwick (Newport, United Kingdom), E. Parkes (Newport, United Kingdom), N. Goyal (Newport, United Kingdom), A. Ionescu (Newport, United Kingdom)
| |
EXPERIENCE WITH RADIOFREQUENCY ABLATION OF LUNG TUMORS
J. Diaz Garcia (Madrid, Spain), M. Morales García (Madrid, Spain), M. Rio Ramirez (Madrid, Spain), F. García Prieto (Madrid, Spain), C. Matesanz López (Madrid, Spain), B. Raboso Moreno (Madrid, Spain), A. Rodriguez (Madrid, Spain), C. Acosta Gutiérrez (Madrid, Spain), A. Abad Fernandez (Madrid, Spain)
| |
Surgery of remnant lung after contralateral pneumonectomy is safe
K. Furrer (Zürich, Switzerland), E. Iliev (Zürich, Switzerland), W. Weder (Zürich, Switzerland), S. Hillinger (Zürich, Switzerland), D. Schneiter (Zürich, Switzerland), I. Inci (Zürich, Switzerland), I. Opitz (Zürich, Switzerland)
| |
Low dose olanzapine for carboplatin-induced nausea and vomiting
C. Sakai (Gifu, Japan), H. Iihara (Gifu, Japan), M. Shimokawa (Minami-ku, Japan), Y. Fujita (Ohta, Japan), S. Ikemura (Shinjuku-ku, Japan), C. Hirose (Gifu, Japan), M. Kotake (Ohta, Japan), N. Funaguchi (Gifu, Japan), T. Gomyo (Gifu, Japan), H. Imai (Ohta, Japan), J. Hakamata (Shinjuku-ku, Japan), D. Kaito (Gifu, Japan), K. Minato (Ohta, Japan), T. Arai (Ohta, Japan), H. Kawazoe (Minato-ku, Japan), A. Suzuki (Gifu, Japan), Y. Ohno (Gifu, Japan), H. Okura (Gifu, Japan)
| |
Genetic polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer
A. Casal (Santiago de Compostela, Spain), M. Torres (vigo, Spain), I. Parente (Orense, Spain), A. Golpe (Santiago de Compostela, Spain), C. Montero (A Coruña, Spain), V. Leiro (Vigo, Spain), O. Castro (Lugo, Spain), A. Fernández (Vigo, Spain), L. Valdés (Santiago de Compostela, Spain), A. Ruano (Santiago de Compostela, Spain)
| |
A prospective study to detect ICIs’ associated Myocarditis, among patients treated for lung cancer
C. Faubry (Bordeaux, France), M. Faure (Bordeaux, France), R. Veillon (Bordeaux, France), C. Vergnenègre (Bordeaux, France), H. Cochet (Bordeaux, France), C. Raherison (Bordeaux, France), P. Domingues Dos Santos (bordeaux, France), Z. Maeva (bordeaux, France)
| |
Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment
R. Estêvão Gomes (Lisboa, Portugal), T. Almodôvar (Lisboa, Portugal)
| |
Influenza and Pneumococcal vaccination effects on the immune-related adverse events in patients under immunotherapy for an advanced stage non-small cell lung cancer
M. MONBRUN (Libourne, France), L. Grassion (Bordeaux, France), E. Blanchard (Bordeaux, France), R. Veillon (Bordeaux, France), M. Zysman (Bordeaux, France), C. Raherison (Bordeaux, France)
| |
Atezolizumab in previously treated non-small-cell lung cancer patients
M. Serino (Porto, Portugal), V. Santos (Porto, Portugal), D. Araújo (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Magalhães (Porto, Portugal), G. Fernandes (Porto, Portugal), H. Queiroga (Porto, Portugal), V. Hespanhol (Porto, Portugal)
| |
Immune-related adverse events as a predictor marker of response to programmed cell death 1/programmed death-ligand 1 axis inhibitors in patients with non-small cell lung cancer.
A. Charpidou (Athens, Greece), V. Patriarcheas (Athens, Greece), I. Vathiotis (Athens, Greece), E. Kokotou (Athens, Greece), N. Syrigos (Athens, Greece), M. Mani (Athens, Greece), L. Stournara (Athens, Greece), I. Gkiozos (Athens, Greece)
| |
Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the „good responder“?
K. Brat (Brno, Czech Republic), J. Skrickova (Brno, Czech Republic), M. Bratova (Brno, Czech Republic), M. Barinova (Brno, Czech Republic), K. Hurdalkova (Brno, Czech Republic), M. Pesek (Pilsen, Czech Republic), M. Svaton (Pilsen, Czech Republic), L. Havel (Prague, Czech Republic), L. Koubkova (Prague, Czech Republic), M. Hrnciarik (Hradec Kralove, Czech Republic), J. Krejci (Prague, Czech Republic), J. Kultan (Olomouc, Czech Republic), O. Fischer (Olomouc, Czech Republic), M. Zemanova (Prague, Czech Republic), M. Cernovska (Prague, Czech Republic), M. Safanda (Prague, Czech Republic), H. Coupkova (Brno, Czech Republic), T. Tuzova (Jihlava, Czech Republic), D. Dolezal (Usti nad Labem, Czech Republic)
| |
An implantable rutin incorporated PCL/collagen electrospun nanofibers for effectivegrowth inhibition of lung cancer cells: Possible application in prevention of lung cancerlocal recurrence
S. celik (Istanbul, Turkey), S. Doosti (Istanbul, Turkey), M. Karimi (Ahvaz, Islamic Republic of Iran)
| |
Patient-reported outcome measures: do they improve the quality of supportive care in advanced non-small cell lung cancer?
M. Kalliri (Athens, Greece), A. Charpidou (Athens, Greece), V. Ramfidis (Athens, Greece), D. Grapsa (Athens, Greece), I. Gkiozos (Athens, Greece), D. Stefanou (Athens, Greece), K. Syrigos (Athens, Greece)
| |
Does long treatment delay affect survival in metastatic non-small cell lung cancer
M. Hamdi (Ariana, Tunisia), F. Chermiti (Ariana, Tunisia), B. Nidhal (Ariana, Tunisia), B. Imen (Ariana, Tunisia), F. Soraya (Ariana, Tunisia)
| |
Prognostic value of neutrophil to lymphocyte ratio in patients with advanced non-small cell lung cancer
S. Koukidou (Athens, Greece), A. Charpidou (Athens, Greece), D. Vassos (Athens, Greece), D. Grapsa (Athens, Greece), S. Ampelioti (Athens, Greece), E. Dimakou (Athens, Greece), P. Bakakos (Athens, Greece), G. Poulakou (Athens, Greece), K. Syrigos (Athens, Greece)
| |
Thromboprophylaxis in lung cancer patients with intermediate tinzaparin dose: The iCaLT study
M. Kouvela (Athens, Greece), D. Stefanou (Athens, Greece), L. Stournara (Athens, Greece), E. Ntalakou (Athens, Greece), F. Sarropoulou (Athens, Greece), N. Syrigos (Athens, Greece), I. Gkiozos (Athens, Greece)
| |
Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement
L. Bitar (Zagreb, Croatia), F. Seiwerth (Zagreb, Croatia), L. Ljubicic (Zagreb, Croatia), A. Bacelic-Gabelica (Zagreb, Croatia), D. Srdic (Zagreb, Croatia), M. Koršic (Zagreb, Croatia), S. Badovinac (Zagreb, Croatia), S. Pleština (Zagreb, Croatia), M. Samaržija (Zagreb, Croatia), M. Jakopovic (Zagreb, Croatia)
| |